BeOne Medicines (ONC) SVP logs option exercises and 2,666-ADS sale

Rhea-AI Filing Summary

BeOne Medicines Ltd. executive Lee Chan Henry, SVP and General Counsel, reported multiple option exercises and ADS trades on August 11, 2026. He exercised three option grants covering a total of 34,658 Ordinary Shares at exercise prices of $14.96, $16.41, and $12.23 per Ordinary Share. In related non-derivative transactions, he acquired blocks of 812, 1,058, and 796 American Depositary Shares (each ADS representing 13 Ordinary Shares), and sold 2,666 ADS at $360.00 per ADS pursuant to a Rule 10b5-1 trading plan adopted on May 29, 2026. Following these transactions, he directly held 325,312 Ordinary Shares.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 8 txns

Insider Lee Chan Henry

Role SVP, General Counsel

Sold 2,666 shs ($960K)

Approx. gross sale proceeds $960K

Approx. exercise cost $510K

Type	Security	Shares	Price	Value
Exercise	Share Option (Right to Buy) F3, F4	10,556	$0.00	$0.00
Exercise	Share Option (Right to Buy) F3, F5	13,754	$0.00	$0.00
Exercise	Share Option (Right to Buy) F3, F6	10,348	$0.00	$0.00
Exercise	American Depositary Shares F1	812	$194.47	$158K
Exercise	American Depositary Shares F1	1,058	$213.32	$226K
Exercise	American Depositary Shares F1	796	$159.03	$127K
Sale	American Depositary Shares F1, F2	2,666	$360.00	$960K
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Share Option (Right to Buy) — 145,951 shares (Direct); American Depositary Shares — 0 shares (Direct); Ordinary Shares — 325,312 shares (Direct)

Footnotes (6)

1. F1. Each American Depositary Share represents 13 Ordinary Shares.
2. F2. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 29, 2026.
3. F3. The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.
4. F4. These securities vest over a four-year period as follows: 25% on July 29, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
5. F5. These securities vest over a four-year period as follows: 25% on the first anniversary of June 15, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
6. F6. These securities vest over a four-year period as follows: 25% on the first anniversary of June 5, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

Key Figures

Options exercised (grant 1): 10,556 Ordinary Shares at $14.96 per share Options exercised (grant 2): 13,754 Ordinary Shares at $16.41 per share Options exercised (grant 3): 10,348 Ordinary Shares at $12.23 per share +5 more

8 metrics

Options exercised (grant 1) 10,556 Ordinary Shares at $14.96 per share Share Option (Right to Buy) exercised on August 11, 2026, expiring August 4, 2032

Options exercised (grant 2) 13,754 Ordinary Shares at $16.41 per share Share Option (Right to Buy) exercised on August 11, 2026, expiring June 14, 2033

Options exercised (grant 3) 10,348 Ordinary Shares at $12.23 per share Share Option (Right to Buy) exercised on August 11, 2026, expiring June 4, 2034

ADS acquired (block 1) 812 ADS at $194.47 per ADS American Depositary Shares acquired on August 11, 2026

ADS acquired (block 2) 1,058 ADS at $213.32 per ADS American Depositary Shares acquired on August 11, 2026

ADS acquired (block 3) 796 ADS at $159.03 per ADS American Depositary Shares acquired on August 11, 2026

ADS sold 2,666 ADS at $360.00 per ADS Sale under Rule 10b5-1 trading plan on August 11, 2026

Post-transaction holdings 325,312 Ordinary Shares Direct ownership after reported transactions

Key Terms

Rule 10b5-1 trading plan, American Depositary Shares, Share Option (Right to Buy), exercise price, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"The sale was effected pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

American Depositary Shares financial

"Each American Depositary Share represents 13 Ordinary Shares."

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

Share Option (Right to Buy) financial

"security_title: Share Option (Right to Buy)"

exercise price financial

"The number of securities underlying each option and the exercise price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Ordinary Shares financial

"The number of securities underlying each option and the exercise price therefor are represented in ordinary shares."

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

What insider activity did BeOne Medicines (ONC) report for Lee Chan Henry?

BeOne Medicines reported that SVP and General Counsel Lee Chan Henry exercised options for 34,658 Ordinary Shares and both acquired and sold American Depositary Shares, including a sale of 2,666 ADS on August 11, 2026.

How many BeOne Medicines (ONC) options did Lee Chan Henry exercise and at what prices?

On August 11, 2026, Lee Chan Henry exercised options covering 10,556, 13,754, and 10,348 Ordinary Shares at exercise prices of $14.96, $16.41, and $12.23 per Ordinary Share, respectively, all represented in Ordinary Shares.

What American Depositary Share (ADS) trades did BeOne Medicines (ONC) disclose for Lee Chan Henry?

The filing shows acquisitions of 812, 1,058, and 796 American Depositary Shares and a sale of 2,666 ADS at $360.00 per ADS. Each ADS represents 13 Ordinary Shares of BeOne Medicines Ltd.

Was the BeOne Medicines (ONC) insider sale by Lee Chan Henry under a Rule 10b5-1 plan?

Yes. The sale of 2,666 American Depositary Shares at $360.00 per ADS was effected under a Rule 10b5-1 trading plan that Lee Chan Henry adopted on May 29, 2026, indicating the trades were pre-arranged.

What are Lee Chan Henry’s reported holdings in BeOne Medicines (ONC) after these transactions?

After the reported August 11, 2026 transactions, Lee Chan Henry is shown as directly holding 325,312 Ordinary Shares of BeOne Medicines Ltd. These holdings exclude any additional derivative positions not listed in this report.

How do BeOne Medicines (ONC) ADS relate to Ordinary Shares in this insider filing?

The filing specifies that each American Depositary Share of BeOne Medicines represents 13 Ordinary Shares. This ratio applies to the reported ADS acquisitions and sale for Lee Chan Henry on August 11, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/13/2026 - 08:55 PM Accepted by SEC EDGAR 08/13/2026 - 08:54 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lee Chan Henry

(Last) (First) (Middle)

C/O BEONE MEDICINES I GMBH

AESCHENGRABEN 27, 21ST FLOOR

(Street)

BASEL 4051

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
BeOne Medicines Ltd. [ ONC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares								325,312	D
American Depositary Shares(1)	08/11/2026		M		812	A	$194.47	812	D
American Depositary Shares(1)	08/11/2026		M		1,058	A	$213.32	1,870	D
American Depositary Shares(1)	08/11/2026		M		796	A	$159.03	2,666	D
American Depositary Shares(1)	08/11/2026		S(2)		2,666	D	$360	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$14.96(3)	08/11/2026		M			10,556	(4)	08/04/2032	Ordinary Shares	10,556	$0	0	D
Share Option (Right to Buy)	$16.41(3)	08/11/2026		M			13,754	(5)	06/14/2033	Ordinary Shares	13,754	$0	57,369	D
Share Option (Right to Buy)	$12.23(3)	08/11/2026		M			10,348	(6)	06/04/2034	Ordinary Shares	10,348	$0	88,582	D

Explanation of Responses:

1. Each American Depositary Share represents 13 Ordinary Shares.

2. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 29, 2026.

3. The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.

4. These securities vest over a four-year period as follows: 25% on July 29, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

5. These securities vest over a four-year period as follows: 25% on the first anniversary of June 15, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

6. These securities vest over a four-year period as follows: 25% on the first anniversary of June 5, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

Remarks:

	/s/ Frank Collazo, as Attorney-in-Fact	08/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)